nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-969EA160·Framework v5.5·Pipeline v0.4·Evaluated 25 Jul 2026·OECD: 3.1 Basic medicine·Subfield: Cancer Research·Basis: Full text·Type: Systematic review or meta-analysis

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.

Cortes et al.Cortes, Haiderali, Huang et al.·2023·BMC cancer·10.1186/s12885-023-11293-4 ↗

Primary claim

Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab confers benefits in response and survival outcomes versus alternative neoadjuvant treatments for early-stage TNBC.

Tentative · broad conclusion rests on sparse, mostly indirect comparisons with favorable results limited by comparator and outcome
In brief

A useful comparative TNBC treatment synthesis for HTA decisions, constrained by a sparse indirect network.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Abstract

BACKGROUND: Patients with triple-negative breast cancer (TNBC) are generally younger and more likely to experience disease recurrence and have the shortest survival among all breast cancer patients. Recently, neoadjuvant delivery of the programmed cell death protein-1 inhibitor pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab was approved for patients with high-risk, early-stage TNBC, but this treatment regimen has not been evaluated in head-to-head trials with other neoadjuvant treatment regimens. Therefore, the objective of this study was to estimate the relative efficacy of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab versus other neoadjuvant treatments for early-stage TNBC through a systematic review and network meta-analysis (NMA).

METHODS: EMBASE, MEDLINE, Cochrane Central Register of Controlled Trials, conference abstracts, and clinical trial registries were searched for randomized controlled trials evaluating neoadjuvant treatments for early-stage TNBC. NMA was performed to estimate relative treatment effects among evaluated interventions.

RESULTS: Five trials met the inclusion criteria and were included in the NMA. The relative efficacy of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab was favorable to paclitaxel followed by anthracycline + cyclophosphamide in terms of pathologic complete response (pCR), event-free survival (EFS), and overall survival; paclitaxel + carboplatin followed by anthracycline + cyclophosphamide in terms of pCR and EFS; paclitaxel + bevacizumab followed by anthracycline + cyclophosphamide + bevacizumab in terms of pCR; and paclitaxel + carboplatin + veliparib followed by anthracycline + cyclophosphamide in terms of EFS.

CONCLUSIONS: Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab confers benefits in response and survival outcomes versus alternative neoadjuvant treatments for early-stage TNBC.

Key Claims

Primary finding · Tentative

Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab confers benefits in response and survival outcomes versus alternative neoadjuvant treatments for early-stage TNBC.

broad conclusion rests on sparse, mostly indirect comparisons with favorable results limited by comparator and outcome

Abstract, Conclusions
Secondary · Supported

The relative efficacy of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab was favorable to paclitaxel followed by anthracycline + cyclophosphamide in terms of pCR, EFS, and OS.

reported NMA estimates are statistically favorable across all three named outcomes

Abstract, Results; Tables 3–5
Secondary · Supported

The relative efficacy of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab was favorable to paclitaxel + carboplatin followed by anthracycline + cyclophosphamide in terms of pCR and EFS.

specific pCR and EFS estimates are favorable, though OS does not meet the same threshold

Abstract, Results; Tables 3–4
Secondary · Supported

The relative efficacy of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab was favorable to paclitaxel + bevacizumab followed by anthracycline + cyclophosphamide + bevacizumab in terms of pCR.

claim is outcome-specific and matches the statistically favorable pCR comparison

Abstract, Results; Table 3
Secondary · Supported

The relative efficacy of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab was favorable to paclitaxel + carboplatin + veliparib followed by anthracycline + cyclophosphamide in terms of EFS.

claim is limited to EFS and aligns with the reported credible interval

Abstract, Results; Table 4

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Clinically focused comparative evidence gap

The study targets the absence of head-to-head comparisons between the approved pembrolizumab regimen and other neoadjuvant treatments for early-stage TNBC. This creates a clear clinical and policy use case for an NMA.

↳ Background

#methodological rigour

Broad search and duplicate review process

The methods report searches of EMBASE, MEDLINE, CENTRAL, conference proceedings, and clinical trial registries, followed by duplicate abstract selection, full-text selection, and data extraction. These procedures support the completeness and reproducibility of the review process.

↳ Methods, Systematic Review

#reporting

Transparent presentation of comparative estimates

The article presents full matrices for pCR, EFS, and OS, including statistically meaningful and non-meaningful comparisons. This lets readers see that favorable findings differ by comparator and outcome rather than applying uniformly.

↳ Results, Tables 3–5

#application pathway

Direct pathway to HTA use

The background explicitly frames NMA as evidence for clinicians, guideline developers, and health technology assessment agencies. The review’s stated purpose aligns with a concrete decision-support pathway.

↳ Background; Methods, Systematic Review

Limitations

#methodological rigour

Sparse network limits comparative confidence

Only one trial connected each treatment in the network, so between-study heterogeneity could not be reliably estimated and a fixed-effects assumption was used. This is a central limitation for the indirect comparisons.

↳ Methods, Feasibility Assessment and Network Meta-analysis

#methodological rigour

Post-review comparator broadening introduced flexibility

After completion of the systematic review, the comparator component of the PICOS was broadened to form a connected network. That change may be defensible for feasibility, but it reduces confidence that the evidence assembly was fully prespecified.

↳ Methods, Systematic Review

#methodological rigour

Transitivity support is incompletely documented

The feasibility assessment notes that baseline patient characteristics were not reported for most trials, yet the NMA depends on assumptions of sufficient similarity across trials. The paper also assumes PD-L1 expression influenced only the pembrolizumab-containing regimen.

↳ Results, Feasibility Assessment; Results, Network Meta-analysis

#contribution

Conclusions are broader than results

The conclusion states that the pembrolizumab regimen is effective compared with other neoadjuvant treatments, while the results show statistically favorable findings only for specific comparators and outcomes. This creates an internal-coherence watch-out rather than a fatal inconsistency.

↳ Conclusions; Results, Tables 3–5

Does this match your read? Add your assessment ↓

Nabu Commentary

The article’s strongest feature is its clinically relevant NMA of five RCTs in a setting where direct comparative trials are absent. The methods are competently described and include broad searching, duplicate review, and Bayesian survival modeling, but the network’s single-study links force a fixed-effects assumption and limit heterogeneity assessment. The feasibility assessment and discussion acknowledge several of these limitations, including the exclusion of CALGB 40603 from primary survival analyses and the inability to estimate between-study heterogeneity. Scores are held in the moderate range because the conclusions and abstract present a broad benefit message while the strongest evidence is comparator- and outcome-specific.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.3±0.2

Contribution
3.4

The contribution is a practically useful comparative synthesis in a setting without comprehensive head-to-head trials. Its advance is moderate because it synthesizes only five trials and most conclusions rest on indirect comparisons rather than new clinical evidence.

Background; Results, Tables 3–5

has not been evaluated in head-to-head trials

Methodological Rigour
3.2

The methods include database, conference, and registry searches, duplicate screening and extraction, PRISMA reporting, and Bayesian NMA procedures. The score is limited by single-study network links, fixed-effects assumptions, incomplete main-text integration of risk of bias, no GRADE certainty assessment, and a post-review comparator broadening.

Methods, Systematic Review; Methods, Feasibility Assessment and Network Meta-analysis

only one trial connected each treatment

Reporting
3.7

The article presents its PICOS criteria, trial characteristics, network structure, and full comparison matrices in a readable sequence. Reporting is reduced slightly because the abstract and conclusions use broader benefit language than the comparator- and outcome-specific results justify.

Table 1; Figures 2–3; Results, Tables 3–5; Conclusions

All bolded values are statistically meaningful

Positioning
3.1

The paper explains the TNBC clinical setting, pembrolizumab approval context, and the role of NMA for clinicians, guideline developers, and HTA agencies. Contextualization is only adequate because the discussion gives limited attention to evidence certainty, risk-of-bias implications, cost/toxicity tradeoffs, and patient subgroups.

Background; Discussion

clinicians, guideline developers, and health technology assessment agencies

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The article is broadly internally consistent, with results tables aligning with the abstract’s named favorable comparisons. Interpretive watch-outs remain because the network was broadened after the initial review and the conclusions generalize beyond some comparator- and outcome-specific findings.

Research ConductClean

No text-grounded conduct problem meets the threshold for a reliability concern. The protocol was not registered, but this is explicitly disclosed and explained as related to health technology assessment submissions.

Flags: 0 declared / 5 total

Reference IntegrityClean

35 references verified via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Breast cancer
Type of advanceSynthesis
Route to useNamed
AdvanceExtends
BeneficiariesLarge
CitationsFWCI 3.5
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The claim rests on a network meta-analysis of five randomized controlled trials including the large multinational phase III KEYNOTE-522 with survival outcomes, constituting validated clinical evidence.

From the paper
“the primary purpose of this systematic review and NMA was to identify and synthesize evidence from the clinical literature to support health technology assessment submissions”

The paper explicitly names health technology assessment bodies, clinicians, guideline developers and policymakers as the actors who would use these comparative findings.

Pathway

Oncologists, guideline developers and health technology assessment agencies would use these comparative efficacy estimates to rank neoadjuvant regimens and guide treatment and reimbursement decisions for early-stage TNBC.

Barrier

The comparisons are indirect, built from a sparse network with one trial per link, a fixed-effects assumption and no head-to-head randomized evidence against the alternative regimens.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Technical feasibility of a long read, fourth generation sequencing platform in diagnostic profiling of clinical routine samples: a proof-of-concept study

    Vitale, Colarossi, Russo, et al. · 2026 · Clinical medicine

    Primary claim

    The adapted ONT workflow demonstrated high concordance rate in detecting clinically relevant molecular alterations on short-read fragments, achieving comparable accuracy with standardized second generation NGS platforms on tissue and liquid biopsy samples.

    Tentative
    Evidence Score
    2.7±0.2
    Reliability
    Caveats
  2. Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

    Weihua Zeng, S. Guo-Dong Li, Shuo Li, et al. · 2026 · Clinical medicine

    Primary claim

    MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3%

    Supported
    Evidence Score
    3.7±0.2
    Reliability
    Caveats
  3. Platelet-derived factors dysregulate placental sphingosine-1-phosphate receptor 2 in human trophoblasts

    Freya Lyssy, Jacqueline Guettler, Beatrice A Brugger, et al. · 2023 · Basic medicine

    Primary claim

    S1PR2 was found to be significantly down-regulated in BeWo cells when co-incubated with platelet-derived factors (P = 0.0055).

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats

How the rubric works →